BriLife

Last updated

BriLife
Reuven Rivlin with the first vaccinator in Phase B of the Israeli Vaccine of the Israeli Biological Institute, January 2021 (GPOABG 4084).jpg
The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center.
Vaccine description
Target SARS-CoV-2
Vaccine type Viral vector
Clinical data
Other namesBrilife
Routes of
administration
Intramuscular
ATC code
  • None

BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate. [1] [2] [3] [4] It was developed by the Israel Institute for Biological Research (IIBR). [1] [5] [6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine. [7] [8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19. [9] [3]

Related Research Articles

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).

Covaxin Vaccine against COVID-19

Covaxin is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

ZF2001 Vaccine against COVID-19

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

CoVLP COVID-19 vaccine candidate produced in a plant

CoVLP is a COVID-19 vaccine candidate developed by Medicago and GlaxoSmithKline (GSK). It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.

EpiVacCorona EpiVacCorona vaccine against COVID-19

EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants.

ZyCoV-D Vaccine candidate against COVID-19

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.

SCB-2019 Vaccine candidate against COVID-19

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.

BBV154 Vaccine candidate against COVID-19

BBV154 is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, American company Precision Virologics and the Washington University School of Medicine in St Louis, Missouri, United States.

Sinopharm WIBP COVID-19 vaccine Vaccine against COVID-19

The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases. The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

MVC COVID-19 vaccine Vaccine against COVID-19

The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine , is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies and the U.S. National Institutes of Health.

Viral vector vaccine Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material coding for a desired antigen into the recipient's host cells. As of April 2021, six viral vector vaccines have been authorized for use in humans in at least one country: four COVID-19 vaccines and two Ebola vaccines.

Walvax COVID-19 vaccine Vaccine candidate against COVID-19

ARCoV, also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine candidate developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. In contrast to other mRNA covid vaccines developed by Pfizer-BioNtech, and Moderna, this vaccine primary aims at the Sars-Cov-2 RBD, rather than spike. It is approved for Phase III trials in China, Mexico, Indonesia, and Nepal.

NDV-HXP-S Vaccine candidate against COVID-19

NDV-HXP-S is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.

Razi Cov Pars Vaccine candidate against COVID-19

Razi Cov Pars is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.

Sputnik Light Vaccine against COVID-19

Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. It will also be used as a third (booster) dose for those who received Sputnik V at least 6 months earlier.

COVI-VAC (U.S. COVID-19 vaccine) Vaccine candidate against COVID-19

COVI-VAC is a COVID-19 vaccine developed by Codagenix, Inc. In December 2020, COVI-VAC started a Phase I clinical trial, involving 48 participants. The trial was scheduled to complete in June 2021, with results to be reported by May 2022. On September 29, 2021, Codagenix presented positive phase 1 data for COVI-VAC at IDWEEK2021. Data indicates that COVI-VAC is well tolerated, with no significant adverse events reported and that administration of the intranasal vaccine was immunogenic and capable of blocking nasal replication of the virus with minimal viral shedding, recorded at levels lower than those likely to result in subsequent transmission of COVID-19. Furthermore, COVI-VAC was shown to stimulate both serum and mucosal antibody immune responses.

COVAX-19 Vaccine candidate against COVID-19

COVAX-19 is the result of a collaboration between Vaxine and CinnaGen, a private company with operations in the Middle East.covax-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian based biotech company Vaxine. It is under clinical trial in collaboration with the Iranian company CinnaGen.

GBP510 Vaccine candidate against COVID-19

GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. Thirty vaccines are authorized for use by national governments, including eight approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.

Soberana Plus Vaccine

Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.

References

  1. 1 2 Karpiński, Tomasz M.; Ożarowski, Marcin; Seremak-Mrozikiewicz, Agnieszka; Wolski, Hubert; Wlodkowic, Donald (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics . 11 (4): 1690–1702. doi:10.7150/thno.53691. ISSN   1838-7640. PMC   7778607 . PMID   33408775.
  2. Bezbaruah, Rajashri; Borah, Pobitra; Kakoti, Bibhuti Bhushan; Al-Shar’I, Nizar A.; Chandrasekaran, Balakumar; Jaradat, Da’san M. M.; Al-Zeer, Munir A.; Abu-Romman, Saeid (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences . 8: 96. doi: 10.3389/fmolb.2021.635337 . ISSN   2296-889X. PMC   8082173 . PMID   33937326.
  3. 1 2 Pushparajah, Deborah; Jimenez, Salma; Wong, Shirley; Alattas, Hibah; Nafissi, Nafiseh; Slavcev, Roderick A. (1 March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews . 170: 113–141. doi:10.1016/j.addr.2021.01.003. ISSN   0169-409X. PMC   7789827 . PMID   33422546.
  4. Venkadapathi, Jeyanthi; Govindarajan, Venkat Kumar; Sekaran, Saravanan; Venkatapathy, Santhi (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences . 8: 637378. doi: 10.3389/fmolb.2021.637378 . ISSN   2296-889X. PMC   8219860 . PMID   34179072.
  5. Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
  6. Scarabel, Lucia; Guardascione, Michela; Dal Bo, Michele; Toffoli, Giuseppe (1 March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases. 104: 441–451. doi:10.1016/j.ijid.2021.01.035. ISSN   1201-9712. PMC   7816887 . PMID   33476760.
  7. Rabinovitch, Ari; Williams, Dan (12 July 2021). Grebler, Dan (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters . Retrieved 10 November 2021.
  8. "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News . 15 August 2021. Retrieved 10 November 2021.
  9. Yahalom-Ronen, Yfat; Tamir, Hadas; Melamed, Sharon; Politi, Boaz; Shifman, Ohad; Achdout, Hagit; Vitner, Einat B.; Israeli, Ofir; Milrot, Elad; Stein, Dana; Cohen-Gihon, Inbar (16 December 2020). Shlomi Lazar, Hila Gutman, Itai Glinert, Lilach Cherry, Yaron Vagima, Shirley Lazar, Shay Weiss, Amir Ben-Shmuel, Roy Avraham, Reut Puni, Edith Lupu, Elad Bar-David, Assa Sittner, Noam Erez, Ran Zichel, Emanuelle Mamroud, Ohad Mazor, Haim Levy, Orly Laskar, Shmuel Yitzhaki, Shmuel C. Shapira, Anat Zvi, Adi Beth-Din, Nir Paran & Tomer Israely. "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications . 11 (1): 6402. doi:10.1038/s41467-020-20228-7. ISSN   2041-1723. PMC   7745033 . PMID   33328475.